Objective: To investigate associations between statin (3-hxydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) use and Parkinson disease (PD).
METHODS Study design. This study is part of the ongoing UCLA Parkinson's Environment and Genes (PEG) Study, a population-based case-control study that recruits incident cases and controls from three rural California counties (Fresno, Tulare, Kern). Cases were identified through practicing neurologists in these counties who provide care for patients with PD (90% of these neurologists participated), as well as through large medical groups (such as Kaiser Permanente, Kern and Visalia Medical Center, and the Veteran's Administration), PD support groups, local newspapers, and local radio stations. An age, gender, and county stratified random sample of Medicare enrollees living in the three counties and residents selected from homes identified at random from all housing units listed on parcel maps for the same tri-county area provided us with controls. Here, we evaluated 312 incident (i.e., enrolled within 3 years of first diagnosis) idiopathic PD cases and 342 controls that were recruited between January 2001 and January 2007.
The study's two UCLA movement disorder specialists confirmed a diagnosis of clinically probable or possible PD for all cases using well-established, stringent diagnostic criteria, 12, 13 and by making multiple patient visits to confirm diagnoses when necessary. A diagnosis of clinically probable or possible PD was confirmed if patients met the following criteria: 1) manifestation of at least two of the following characteristics: resting tremor, bradykinesia, or cogwheel rigidity, at least one of which is resting tremor or bradykinesia; 2) no suggestion of a parkinsonian syndrome due to trauma, brain tumor, infection, cerebrovascular disease, or other known neurologic disease, and no treatment in the past with dopamine-blocking or dopamine-depleting agents; 3) no atypical features such as prominent oculomotor palsy, cerebellar signs, vocal cord paresis, severe orthostatic hypotension, pyramidal signs, amyotrophy, or limb apraxia; 4) asymmetric onset; and 5) if treatment with levodopa had been initiated, symptomatic improvement after treatment. Probable cases met criteria 1 through 5. Possible cases exhibited at least one characteristic from criterion 1 and fulfilled criteria described in 2 and 3. Although sometimes included under criterion 1, postural reflex impairment was excluded as a criterion because it usually occurs late in PD and may typically occur early in other parkinsonian disorders (i.e., multiple system atrophy and vascular parkinsonism). 14 Study participants completed a medical questionnaire providing information on the specific statins they took, length of treatment in months or years, and age at first and last use. Demographic and lifestyle characteristics were collected by telephone interviewers blinded to a subject's case/ control status. All subjects provided informed consent and the study was approved by the UCLA Institutional Review Board.
Statistical analysis. Participants were categorized as ever or never users of all and each individual statin. For cases, any use that occurred post-diagnosis was ignored. ORs for ever vs never use of statins were calculated using unconditional logistic regression, controlling for age continuously (age at diagnosis for cases and age at interview for controls), gender, smoking pack-years (0, Ͼ0 to Ͻ10, Ն10 to Ͻ40, Ն40), education (Ͻ12 years, 12 years, Ͼ12 years), race (Caucasian, Asian, Latino, Native American, and black), and county of residence (Kern, Tulare, Fresno). We adjusted for these variables because previous literature indicated they could be potential confounders of an association between PD and statin use. A small number (n ϭ 9; 5 cases, 4 controls) of participants indicated that they used statins but did not report age at first or last use, or duration of use. We performed analyses both excluding these individuals, and also including them as statin users after assigning to them the mean duration of use for cases or controls. We also stratified statin use by duration in years, age at diagnosis/interview (Յ60 years, Ͼ60 years), and gender, assessing potential heterogeneity in effect estimates using the Breslow-Day test (B-D test) for homogeneity. We also analyzed our data after removing all cases that were diagnosed up to 3 years prior to 2001. This was done to account for potential temporal trends in statin prescription and usage because cases could have been diagnosed up to 3 years prior to the start of enrollment and interview in 2001. Finally, we performed a lagged analysis by excluding any use that had occurred during the 5 years immediately prior to the diagnosis for cases or the interview for controls.
RESULTS
Study population characteristics are presented in table 1. The median age of cases was 70.0 years (Ϯ10.6) and the median age of controls was 69.0 years (Ϯ12.7). A total of 18.7% of the population reported ever having taken statins. Among 47 cases who reported ever taking statins, 11 cases reported only post-diagnosis use and, thus, were considered nonusers in all analyses. Among statin users, specific statin use included atorvastatin (48.7%), simvastatin (26.1%), lovastatin (15.3%), pravastatin (9.9%), rosuvastatin (4.5%), and other (1.8%), with some individuals reporting the use of more than one type of statin.
The average age at first use was 65.5 years (47 to 78 years) for cases and 64.6 years (40 to 82 years) for controls, with controls reporting a slightly longer mean duration of use (4.4 years) than cases (3.8 years). A higher frequency of controls reported ever using statins compared to cases, thus suggesting a 55% reduction in PD risk among ever statin users. When evaluating duration of use, we noted a strong dose-response relation, with long-term users (Ն5 years) showing the strongest protective association (table 2) . Results were similar when including subjects with missing statin duration/ age data (ever vs never use, OR 0.46; 95% CI 0.30 to 0.71) and when lagging/excluding use within 5 years of diagnosis or interview (OR 0.33; 95% CI 0.14 to 0.80). When excluding cases diagnosed before 2001, we still noted a strong protective effect for ever vs never statin users (OR 0.49; 95% CI 0.29 to 0.82) as well as for short and longer-term users (Ն1 year, OR 0.43; 95% CI 0.15 to 1.20; Ն5 years, OR 0.50; 95% CI, 0.23 to 1.10). We noticed no difference in effect estimates between men (OR 0.48; 95% CI 0.27 to 0.86) and women (OR 0.41; 95% CI, 0.20 to 0.84). A protective effect was evident in both younger (Յ60) and older age at diagnosis/interview, with a slightly stronger protective effect in the younger age group (Յ60, OR 0.25; 95% CI 0.07 to 0.88; Ͼ60, OR 0.47; 95% CI 0.29 to 0.76), although the CIs largely overlap (B-D test p ϭ 0.90). Similarly, we noticed a slightly stronger protective association for ever/ never statin use among never smokers (OR 0.35; 95% CI 0.17, 0.70) compared to ever smokers (OR 0.57; 95% CI 0.32, 1.02) (B-D test p ϭ 0.25), but the CIs of the estimates also largely overlapped. When evaluating use of each individual statin we noted 60 to 70% risk reductions for all statins except pravastatin (atorvastatin OR 0.39; 95% CI 0.21 to 0.71, simvastatin OR 0.38; 95% CI 0.16 to 0.91, lovastatin OR 0.27; 95% CI 0.09 to 0.87, pravastatin OR 1.78; 95% CI 0.43 to 7.42).
DISCUSSION
In our population-based case control study of incident PD, we observed a protective association between statin use and PD risk and a strong dose-response relation with increasing duration of use. Adjustment for potential confounders did little to change the magnitude of the observed association. Excluding cases whose diagnosis occurred before 2001-the year we started enrollment of our population controlsdemonstrated that the inverse associations observed were not solely due to recent trends in the use of these drugs or in medical prescription practices.
Non-differential misclassification of disease is expected to be minimal due to our study's stringent diagnostic criteria and (repeated if necessary) clinical examination of every PD case by the study's movement disorder specialists (J.B. and Y.B.). There is a possibility of non-differential misclassification because statin use was selfreported, especially when asking participants to recall specific drugs and duration of use. However, studies have demonstrated fair recall of prescription drug use with consistently high specificity 15 and recall is likely even better because statins are fairly new drugs with use occurring at most 15 to 20 years ago and most users continuing to currently use their prescribed statin. Finally, while this is a population-based study with matched controls having been selected at random from a well-defined source population, the possibility of selection bias in our study cannot be ruled out. Specifically, access to healthcare may affect statin use and may have also influenced the self-selection and participation of patients in our study different from controls, i.e., patients with PD were generally in regular contact with medical providers. Thus, patients with PD might have been more likely than population controls to be evaluated and receive treatment for high cholesterol conditions and the expected bias would have been toward finding no association, i.e., patients with PD would be expected to be prescribed more statins than controls. All statins were inversely associated with PD except for pravastatin, although small size of each subgroup limited these comparisons. A possible explanation for pravastation being the exception might be postulated differences in statins' lipophilic properties. There is a general consensus in the literature that pravastatin is the least lipophilic statin resulting in its difficulty in crossing the blood-brain barrier and thus its ability to affect the CNS; yet another report claims that atorvastatin also has low CNS penetration. 16 Interestingly, the only previous study to examine associations between statins and prevalent PD also reported a protective effect, even after adjustment for LDL-C concentration. 4 However, this study relied heavily on statin use for the postdiagnosis period and prevalent PD cases with a moderate to long duration of disease. Postdiagnosis statin use may not properly reflect prediagnosis use. For example, in our study population, 23% of cases who reported ever taking statins reported only post-diagnosis use; we considered all such individuals as nonusers in our analyses of pre-diagnosis statin use.
At this point we are reluctant to ascribe causality to the observed protective association with statin use prior to PD diagnosis. There is some suggestion that low LDL cholesterol may increase the risk of PD. 4, 5 If low LDL cholesterol levels indeed increase risk of PD etiologically, we could be observing a lower risk of PD among subjects who were prescribed statins because of their higher cholesterol levels, i.e., statin use would serve as an indicator of high LDL cholesterol level which would be preventative of PD. Statin use may also be serving as an indicator of high levels of serum coenzyme Q10, for which serum cholesterol is an important determinant. Coenzyme Q10 acts as an antioxidant and electron acceptor for complex I and II in the mitochondrial respiratory chain. 5 The observed protective association when statins were only used for 1 year or less may be suggestive of a biologic mechanism other than statins acting truly protectively. On the other hand, it is plausible that statins are themselves causally associated with PD or at least contribute to the observed protective effect. The possibility of a causal association is supported by our finding of a dose-response relation with duration of use and considerable biologic evidence that statins can be neuroprotective through a variety of mechanisms including NOS and NO regulation, antioxidant effects, and reducing the induction of proinflammatory mediators such as cytokines.
Further investigation of the potential role for statins, cholesterol, and coenzyme Q10 in PD etiology is warranted given our study findings. Due to the nature of the relationship between LDL cholesterol, statin use (an intermediate), and PD, a longitudinal study design, including measures of cholesterol levels over time, is necessary to further investigate this potential causal chain.
